UKJ2 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €3.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.01M
Enterprise Value-€18.21
Total Cash (Recent Filing)€172.47M
Total Debt (Recent Filing)€141.65M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding170,997,270
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.00
Price to Sales (P/S)1215.83
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€175.37K
Bulls Say, Bears Say
Bulls Say
Innovative Product PipelineOPT-302 targets VEGF-C and VEGF-D, offering a novel approach to treating wet AMD and DME. This innovative pipeline positions Opthea to potentially capture significant market share in the eye disease treatment sector.
Strategic Partnerships PotentialPotential partnerships with larger pharmaceutical companies could provide Opthea with the necessary resources for distribution and marketing, enhancing its commercialization capabilities and revenue streams.
Focus On High-Growth MarketBy targeting wet AMD and DME, Opthea is positioned in a high-growth market driven by an aging population and increasing prevalence of eye diseases, which supports long-term demand for its therapies.
Bears Say
High LeverageHigh leverage and negative equity suggest potential solvency issues, limiting financial flexibility and increasing risk, which could hinder long-term operational stability and growth.
Negative Cash FlowNegative cash flows highlight cash management issues, indicating reliance on external funding and potential difficulties in sustaining operations without strategic financial improvements.
Persistent LossesOngoing losses and negative profit margins reflect operational inefficiencies, challenging Opthea's ability to achieve profitability and necessitating strategic changes to improve financial performance.
Ceryvyn Therapeutics Limited News
UKJ2 FAQ
What was Ceryvyn Therapeutics Limited’s price range in the past 12 months?
Ceryvyn Therapeutics Limited lowest stock price was €0.02 and its highest was €3.00 in the past 12 months.
What is Ceryvyn Therapeutics Limited’s market cap?
Ceryvyn Therapeutics Limited’s market cap is €10.01M.
When is Ceryvyn Therapeutics Limited’s upcoming earnings report date?
Ceryvyn Therapeutics Limited’s upcoming earnings report date is Aug 28, 2026 which is in 30 days.
How were Ceryvyn Therapeutics Limited’s earnings last quarter?
Ceryvyn Therapeutics Limited released its earnings results on Mar 01, 2026. The company reported €1.277 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ceryvyn Therapeutics Limited overvalued?
According to Wall Street analysts Ceryvyn Therapeutics Limited’s price is currently Overvalued.
Does Ceryvyn Therapeutics Limited pay dividends?
Ceryvyn Therapeutics Limited does not currently pay dividends.
What is Ceryvyn Therapeutics Limited’s EPS estimate?
Ceryvyn Therapeutics Limited’s EPS estimate is 0.
How many shares outstanding does Ceryvyn Therapeutics Limited have?
Ceryvyn Therapeutics Limited has 170,997,270 shares outstanding.
What happened to Ceryvyn Therapeutics Limited’s price movement after its last earnings report?
Ceryvyn Therapeutics Limited reported an EPS of €1.277 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ceryvyn Therapeutics Limited?
Currently, no hedge funds are holding shares in DE:UKJ2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ceryvyn Therapeutics Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Technical Analysis
Lexicon Pharmaceuticals
―
Prothena
―
RegenXBio
―
Corvus Pharmaceuticals
―
Solid Biosciences
―